Complete Filing Data
Clearmind Medicine Inc. reported Cash And Cash Equivalents of $3.92 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Clearmind Medicine Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Research And Development Expense | $2.1M | $1.4M | $1.5M | $3.1M | $473.7K | |
| Profit Loss Before Tax | -$3.8M | -$4.9M | -$8.6M | -$6.9M | -$2.7M | -$412.9K |
| General And Administrative Expense | $3.6M | $4.4M | $4.8M | $3.2M | $2.2M | $233.2K |
| Profit Loss | -$3.9M | -$5.3M | -$8.6M | -$6.9M | -$2.7M | -$412.9K |
| Income Tax Expense Continuing Operations | $70.4K | $378.0K | $17.4K | $29.9K | ||
| Comprehensive Income | -$3.9M | -$5.3M | -$8.6M | -$6.9M | -$2.7M | |
| Interest Expense On Lease Liabilities | $3.9K | $5.4K | $2.9K | $14.4K | ||
| Adjustments For Income Tax Expense | $70.4K | $103.9K | $17.4K | $29.9K | ||
| Income Taxes Paid Classified As Operating Activities | $229.9K | $306.6K | $12.7K | |||
| Adjustments For Interest Expense | $5.4K | $2.9K | $14.4K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $3.9M | $6.6M | $5.4M | $128.8K | $3.4M | $241.7K | $688.00 |
| Cash Flows From Used In Operating Activities | -$4.7M | -$4.9M | -$6.3M | -$3.7M | -$2.1M | -$264.5K | |
| Adjustments For Increase Decrease In Trade Account Payable | $82.8K | -$198.6K | -$620.4K | $913.3K | $251.7K | -$7.4K | |
| Cash Flows From Used In Financing Activities | $2.6M | $6.3M | $11.7M | $511.7K | $5.4M | $598.7K | |
| Trade And Other Current Receivables Due From Related Parties | $286.5K | $131.8K | $286.5K | $47.0K | |||
| Retained Earnings | -$27.9M | -$24.0M | -$18.8M | -$10.1M | -$4.4M | ||
| Noncurrent Assets | $135.3K | $167.2K | $158.7K | $391.7K | $238.6K | ||
| Intangible Assets Other Than Goodwill | $97.4K | $108.3K | $119.3K | $130.3K | $198.0K | ||
| Equity And Liabilities | $6.1M | $7.3M | $6.0M | $826.4K | $5.2M | ||
| Current Assets | $5.9M | $7.1M | $5.8M | $434.7K | $4.9M | ||
| Adjustments For Decrease Increase In Trade And Other Receivables | $17.2K | $64.9K | -$154.6K | $19.9K | -$115.6K | ||
| Accumulated Other Comprehensive Income | -$21.3K | -$21.3K | -$21.3K | -$21.3K | |||
| Trade And Other Current Payables To Related Parties | $60.2K | $49.0K | $42.4K | $206.5K | $8.3K | ||
| Cash Flows From Used In Investing Activities | -$542.0K | -$238.1K | -$26.2K | -$5.6K | -$184.0K | -$5.1K | |
| Liabilities | $4.9M | $4.1M | $5.0M | $1.9M | $357.2K | ||
| Increase Decrease Through Exercise Of Warrants Equity | $437.0K | $4.7M | $574.0K | $375.0K | |||
| Current Restricted Cash And Cash Equivalents | $20.6K | $7.2K | $37.7K | $14.7K | $20.0K | ||
| Assets | $6.1M | $7.3M | $6.0M | $826.4K | $5.2M | ||
| Other Current Receivables | $35.8K | $49.0K | $104.3K | $50.9K | |||
| Current Accrued Expenses And Other Current Liabilities | $682.2K | $526.1K | $617.0K | $1.4M | |||
| Adjustments For Decrease Increase In Derivative Financial Assets | $68.6K | $107.6K | $308.2K | ||||
| Changes In Fair Value Of Shortterm Investments | -$844.5K | $68.6K | $107.6K | $308.2K | |||
| Rightofuse Assets | $17.4K | $51.7K | $35.7K | ||||
| Current Lease Liabilities | $18.8K | $36.7K | $38.4K | ||||
| Cash Flows From Used In Decrease Increase In Restricted Cash And Cash Equivalents | -$13.5K | $33.8K | -$26.2K | -$14.7K | |||
| Depreciation Rightofuse Assets | $38.4K | $39.0K | $35.4K | $60.7K | |||
| Current Liabilities | $4.9M | $4.1M | $5.0M | ||||
| Property Plant And Equipment | $1.7K | $12.9K | $20.6K | ||||
| Current Warrant Liability | $2.4M | $3.5M | $4.3M | ||||
| Issue Of Equity | $1.5M | $1.5M | $5.7M | $650.0K | |||
| Current Investments | $1.7M | $289.4K | $86.1K | ||||
| Shortterm Investments Classified As Cash Equivalents | $86.1K | $193.8K | |||||
| Current Derivative Financial Liabilities | $290.6K | ||||||
| Noncurrent Liabilities | $16.4K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents | -$2.7M | $1.1M | $5.3M | -$3.2M | $3.1M | $329.2K |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $3.2K | -$11.5K | -$37.7K | -$22.7K | ||
| Payments Of Lease Liabilities Classified As Financing Activities | $42.5K | $42.6K | $40.9K | $70.9K | ||
| Proceeds From Exercise Of Warrants | $415.1K | $4.1M | $590.1K | $795.1K | $7.4M | $598.7K |
| Proceeds From Issue Of Ordinary Shares | 2.2M | 11.1M | 582.6K | 5.4M | ||
| Proceeds From Sales Or Maturity Of Financial Instruments Classified As Investing Activities | $186.1K | $78.5K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Shares | 127.1K | 77.5K | 5.1K | 43.3K | 30.9K | 543.9K |
| Diluted Earnings Loss Per Share | $-30.35 | $-67.80 | $-1,703.04 | $-159.11 | $-88.16 | $-0.76 |
| Basic Earnings Loss Per Share | $-30.35 | $-67.80 | $-1,703.04 | $-159.11 | $-88.16 | $-0.76 |
| Adjusted Weighted Average Shares | 127.1K | 77.5K | 5.1K | 43.3K | 30.9K | 543.9K |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Expense | $5.7M | $5.7M | $6.3M | $6.3M | $2.7M | $233.2K |
| Finance Income Cost | $1.9M | $868.2K | -$2.3M | -$613.6K | -$24.6K | |
| Gains Losses On Change In Fair Value Of Derivatives | $1.1M | $707.8K | -$2.2M | -$290.6K | ||
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | $3.4K | -$6.0K | -$78.1K | |||
| Adjustments For Sharebased Payments | $805.9K | $998.9K | $834.8K | $1.2M | $619.9K | |
| Adjustments For Decrease Increase In Prepaid Expenses | $4.4K | -$3.7K | -$26.1K | $103.0K | -$117.3K | |
| Other Finance Income Cost | -$36.2K | -$10.9K | -$14.4K | |||
| Adjustments For Amortisation Expense | $11.0K | $11.0K | $11.0K | $14.8K | ||
| Share Premium | $26.4M | $24.2M | $17.1M | $6.7M | $7.9M | |
| Current Prepaid Expenses | $39.9K | $44.2K | $40.4K | $14.2K | $160.1K | |
| Adjustments For Increasedecrease In Due To Related Parties | -$144.1K | $7.2K | -$167.9K | $200.4K | -$143.00 | |
| Interest Received Classified As Operating Activities | $132.9K | $271.8K | $71.7K | $8.00 | ||
| Adjustments For Unrealised Foreign Exchange Losses Gains | -$3.6K | $6.1K | $78.2K | |||
| Warrant Reserve | $459.3K | $459.3K | $459.3K | $459.1K | ||
| Increase Decrease Through Sharebased Payment Transactions | $805.9K | $1.3M | $313.2K | $1.1M | ||
| Interest Income On Deposits | $132.9K | $271.2K | $70.1K | |||
| Adjustments For Depreciation Expense | $1.1K | $11.2K | $7.6K | $1.9K | ||
| Unrealized Loss On Shortterm Investment | $107.6K | $308.2K | ||||
| Reserve Of Sharebased Payments | $2.2M | $2.5M | $2.2M | |||
| Adjustments For Gains Losses On Change In Fair Value Of Derivatives | $1.1M | $707.8K | -$2.2M | -$290.6K | ||
| Adjustments For Losses Gains On Shortterm Investment | $107.6K | $308.2K | ||||
| Amortisation Expense | $35.4K | $60.7K | ||||
| Reserve Of Exchange Differences On Translation | $2.2M | $1.9M | $839.5K | |||
| Other Expense By Function | $19.5K | $36.2K | $10.9K | |||
| Foreign Exchange Loss | $6.0K | $78.1K | $404.00 | $24.6K |
Most recent annual filing with the SEC: January 20, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.